{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:48:04Z","timestamp":1781765284606,"version":"3.54.5"},"reference-count":34,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"vor","delay-in-days":47,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01-DK-61212"],"award-info":[{"award-number":["U01-DK-61212"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01-DK-61230"],"award-info":[{"award-number":["U01-DK-61230"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01-DK-61239"],"award-info":[{"award-number":["U01-DK-61239"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01-DK-61242"],"award-info":[{"award-number":["U01-DK-61242"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>In the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study, metformin plus rosiglitazone (M + R) maintained glycemic control better than metformin alone (M) or metformin plus lifestyle (M + L) in youth with type 2 diabetes (T2D). We hypothesized that changes in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) would explain the differential treatment effects on glycemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESEARCH DESIGN AND METHODS<\/jats:title><jats:p>In 626 youth ages 11\u201317 years with T2D duration &amp;lt;2 years, VAT and SAT were estimated by DXA at baseline and at 6 and 24 months. Changes from baseline were analyzed in linear mixed models.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Baseline mean age was 13.9 years, 66.4% were female, 72.2% were Hispanic\/non-Hispanic black, and 20.3% were non-Hispanic white (NHW). Mean BMI was 33.7 kg\/m2. VAT increased more in M + R (13.1%) than M + L (3.9%, P = 0.0006) or M (6.5%, P = 0.0146). SAT also increased more in M + R (13.3%) than in M + L (5.4%, P &amp;lt; 0.0001) or M (6.4%, P = 0.0005), indicating no significant fat redistribution in M + R. In NHWs, VAT increased more in M + R than M (P = 0.0192) and M + L (P = 0.0482) but did not explain the race-ethnicity differences in treatment effects on glycemic control among treatment groups. VAT and SAT increases correlated with higher HbA1c, lower insulin sensitivity, and lower oral disposition index (all P &amp;lt; 0.05), but associations did not differ by treatment group.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>In contrast to the existing reports in adults with T2D, in TODAY, M + R resulted in the most VAT accumulation compared with M + L or M. Differential effects on depot-specific indirect measures of adiposity are unrelated to treatment effects in sustaining glycemic control. Additional studies are needed to understand the clinical markers of metabolic risk profile in youth with T2D on rosiglitazone.<\/jats:p><\/jats:sec>","DOI":"10.2337\/dc18-1935","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T01:25:15Z","timestamp":1559784315000},"page":"1549-1559","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":20,"title":["Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study"],"prefix":"10.2337","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct00081328","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"given":"Ruban","family":"Dhaliwal","sequence":"first","affiliation":[{"name":"State University of New York Upstate Medical University, Syracuse, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Shepherd","sequence":"additional","affiliation":[{"name":"University of Hawaii, Honolulu, HI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4223-8407","authenticated-orcid":false,"given":"Laure","family":"El ghormli","sequence":"additional","affiliation":[{"name":"George Washington University Biostatistics Center, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Copeland","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences Center, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Geffner","sequence":"additional","affiliation":[{"name":"The Saban Research Institute, Children\u2019s Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Higgins","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne L.","family":"Levitsky","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen J.","family":"Nadeau","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth S.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"State University of New York Upstate Medical University, Syracuse, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"White","sequence":"additional","affiliation":[{"name":"Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"2022031300220239500_B1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa1610187","article-title":"Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012","volume":"376","author":"Mayer-Davis","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031300220239500_B2","first-page":"2","article-title":"Ectopic fat deposition and the metabolic syndrome in obese children and adolescents","volume":"71","author":"Cali","year":"2009","journal-title":"Horm Res"},{"key":"2022031300220239500_B3","doi-asserted-by":"crossref","first-page":"E385","DOI":"10.1152\/ajpendo.00052.2008","article-title":"Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls","volume":"295","author":"Misra","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031300220239500_B4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1399-5448.2007.00237.x","article-title":"Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes","volume":"8","author":"Zeitler","year":"2007","journal-title":"Pediatr Diabetes"},{"key":"2022031300220239500_B5","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1109333","article-title":"A clinical trial to maintain glycemic control in youth with type 2 diabetes","volume":"366","author":"Zeitler","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031300220239500_B6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","article-title":"PPAR-\u03b3: adipogenic regulator and thiazolidinedione receptor","volume":"47","author":"Spiegelman","year":"1998","journal-title":"Diabetes"},{"key":"2022031300220239500_B7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes","volume":"51","author":"Mayerson","year":"2002","journal-title":"Diabetes"},{"key":"2022031300220239500_B8","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.2337\/dc12-2534","article-title":"Treatment effects on measures of body composition in the TODAY clinical trial","volume":"36","author":"TODAY Study Group","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031300220239500_B9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2006-1268","article-title":"Review: peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism","volume":"92","author":"Sharma","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300220239500_B10","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2337\/dc12-2393","article-title":"Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and \u03b2-cell function in TODAY","volume":"36","author":"Arslanian","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031300220239500_B11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2337\/dc16-0455","article-title":"Adiponectin, insulin sensitivity, \u03b2-cell function, and racial\/ethnic disparity in treatment failure rates in TODAY","volume":"40","author":"Arslanian","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031300220239500_B12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/oby.2011.367","article-title":"Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat","volume":"20","author":"Micklesfield","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"2022031300220239500_B13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ijpo.249","article-title":"Visceral adipose tissue measured by DXA correlates with measurement by CT and is associated with cardiometabolic risk factors in children","volume":"10","author":"Bosch","year":"2015","journal-title":"Pediatr Obes"},{"key":"2022031300220239500_B14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jocd.2013.05.007","article-title":"How comparable are Hologic and GE-Lunar visceral fat analyses","volume":"16","author":"Fan","year":"2013","journal-title":"J Clin Densitom"},{"key":"2022031300220239500_B15","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/dme.12512","article-title":"Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial","volume":"31","author":"Punthakee","year":"2014","journal-title":"Diabet Med"},{"key":"2022031300220239500_B16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/diabetes.52.2.283","article-title":"Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects","volume":"52","author":"Virtanen","year":"2003","journal-title":"Diabetes"},{"key":"2022031300220239500_B17","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2337\/diacare.26.7.2069","article-title":"Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes","volume":"26","author":"Iozzo","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031300220239500_B18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/oby.2002.137","article-title":"Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients","volume":"10","author":"Carey","year":"2002","journal-title":"Obes Res"},{"key":"2022031300220239500_B19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/dc09-1825","article-title":"Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031300220239500_B20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/oby.2010.59","article-title":"Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study","volume":"18","author":"Preis","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"2022031300220239500_B21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3945\/ajcn.112.047787","article-title":"Clinical utility of visceral adipose tissue for the identification of cardiometabolic risk in white and African American adults","volume":"97","author":"Katzmarzyk","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"2022031300220239500_B22","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1007\/s00125-012-2639-5","article-title":"The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk","volume":"55","author":"Kaess","year":"2012","journal-title":"Diabetologia"},{"key":"2022031300220239500_B23","doi-asserted-by":"crossref","first-page":"E1056","DOI":"10.1210\/jc.2014-4032","article-title":"The association between subcutaneous fat density and the propensity to store fat viscerally","volume":"100","author":"Yeoh","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300220239500_B24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1017\/S0954422409990096","article-title":"Visceral adipose tissue in children and adolescents: a review","volume":"22","author":"Suliga","year":"2009","journal-title":"Nutr Res Rev"},{"key":"2022031300220239500_B25","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/j.2047-6310.2012.00073.x","article-title":"Adiposity in children and adolescents: correlates and clinical consequences of fat stored in specific body depots","volume":"7","author":"Katzmarzyk","year":"2012","journal-title":"Pediatr Obes"},{"key":"2022031300220239500_B26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature01705","article-title":"Cloning of adiponectin receptors that mediate antidiabetic metabolic effects","volume":"423","author":"Yamauchi","year":"2003","journal-title":"Nature"},{"key":"2022031300220239500_B27","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1172\/JCI29126","article-title":"Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome","volume":"116","author":"Kadowaki","year":"2006","journal-title":"J Clin Invest"},{"key":"2022031300220239500_B28","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0026-0495(03)00195-1","article-title":"Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus","volume":"52","author":"Yatagai","year":"2003","journal-title":"Metabolism"},{"key":"2022031300220239500_B29","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.peptides.2010.02.004","article-title":"Regulation of beta-cell viability and gene expression by distinct agonist fragments of adiponectin","volume":"31","author":"Brown","year":"2010","journal-title":"Peptides"},{"key":"2022031300220239500_B30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1463-1326.2012.01626.x","article-title":"Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPAR\u03b3-dependent and PPAR\u03b3-independent mechanisms","volume":"14","author":"Rao","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031300220239500_B31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nm0506-511","article-title":"Overcoming insulin resistance with CNTF","volume":"12","author":"Ahima","year":"2006","journal-title":"Nat Med"},{"key":"2022031300220239500_B32","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.2337\/diabetes.51.10.2968","article-title":"The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects","volume":"51","author":"Yu","year":"2002","journal-title":"Diabetes"},{"key":"2022031300220239500_B33","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/diacare.25.2.376","article-title":"Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients","volume":"25","author":"Yang","year":"2002","journal-title":"Diabetes Care"},{"key":"2022031300220239500_B34","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1463-1326.2008.00880.x","article-title":"Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients","volume":"10","author":"Miyazaki","year":"2008","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc18-1935","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/8\/1549\/529422\/dc181935.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/8\/1549\/529422\/dc181935.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T06:11:56Z","timestamp":1721369516000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/8\/1549\/36199\/Changes-in-Visceral-and-Subcutaneous-Fat-in-Youth"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,6,5]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc18-1935","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,5]]}}}